Annexon, Inc. (ANNX)
NASDAQ: ANNX · Real-Time Price · USD
5.60
+0.22 (4.09%)
At close: Feb 27, 2026, 4:00 PM EST
5.76
+0.16 (2.86%)
After-hours: Feb 27, 2026, 7:45 PM EST
Annexon Employees
Annexon had 100 employees as of December 31, 2024. The number of employees increased by 29 or 40.85% compared to the previous year.
Employees
100
Change (1Y)
29
Growth (1Y)
40.85%
Revenue / Employee
n/a
Profits / Employee
-$2,109,909
Market Cap
834.71M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Arvinas | 430 |
| KalVista Pharmaceuticals | 270 |
| Prime Medicine | 214 |
| Omeros | 202 |
| Janux Therapeutics | 109 |
| AgomAb Therapeutics NV | 58 |
| Arbutus Biopharma | 44 |
| Bright Minds Biosciences | 26 |
ANNX News
- 4 days ago - Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 11 days ago - Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy - GlobeNewsWire
- 5 weeks ago - Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases - Seeking Alpha
- 6 weeks ago - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 - GlobeNewsWire
- 7 weeks ago - Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome - GlobeNewsWire
- 7 weeks ago - Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire